<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IMR</journal-id>
<journal-id journal-id-type="hwp">spimr</journal-id>
<journal-id journal-id-type="nlm-ta">International Medical Research</journal-id>
<journal-title>Journal of International Medical Research</journal-title>
<issn pub-type="ppub">0300-0605</issn>
<issn pub-type="epub">1473-2300</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0300060513475743</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300060513475743</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Clinical Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The value of preoperative PET–CT in papillary thyroid cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kim</surname><given-names>Byung Seup</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513475743">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ryu</surname><given-names>Han Suk</given-names></name>
<xref ref-type="aff" rid="aff2-0300060513475743">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kang</surname><given-names>Kyung Ho</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513475743">1</xref>
<xref ref-type="corresp" rid="corresp1-0300060513475743"/>
</contrib>
</contrib-group>
<aff id="aff1-0300060513475743"><label>1</label>Department of Surgery, Chung-Ang University Hospital, Seoul, Republic of Korea</aff>
<aff id="aff2-0300060513475743"><label>2</label>Department of Pathology, Chung-Ang University Hospital, Seoul, Republic of Korea</aff>
<author-notes>
<corresp id="corresp1-0300060513475743">Dr Kyung Ho Kang, Department of Surgery, Chung-Ang University College of Medicine, Chung-Ang University Hospital, 224-1, Heuk Seok-Dong, Dongjak-Ku, Seoul, 156-755, Republic of Korea. Email: <email>poplipss@paran.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>2</issue>
<fpage>445</fpage>
<lpage>456</lpage>
<history>
<date date-type="received"><day>10</day><month>9</month><year>2012</year></date>
<date date-type="accepted"><day>20</day><month>9</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec>
<title>Objective</title>
<p>To evaluate the clinical usefulness of preoperative positron emission tomography–computed tomography (PET–CT) in primary papillary thyroid cancer (PTC).</p>
</sec>
<sec>
<title>Methods</title>
<p>Preoperative PET–CT scans of patients with biopsy-confirmed PTC who were undergoing thyroidectomy were examined and the maximum standardized uptake value (SUV<sub>max</sub>) of 2-deoxy-2-(<sup>18</sup>F)fluoro-<sc>d</sc>-glucose (<sup>18</sup>F-FDG) was calculated. Demographic and clinical data were obtained from medical records. Tumour tissue was pathologically classified according to World Health Organization guidelines. Univariate and multivariate analyses were performed to determined the demographic, clinical and pathological factors affecting PET positivity and SUV<sub>max</sub>.</p>
</sec>
<sec>
<title>Results</title>
<p>The study included 194 patients. Multivariate analysis indicated that patients were significantly more likely to be PET positive if they were female, had larger tumours (&gt;1 cm), coexisting pathology (nodular hyperplasia or Hashimoto’s thyroiditis) or nonfollicular variant PTC. SUV<sub>max</sub> &lt;2.0 indicated possible follicular variant PTC.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>PET-positive results were unrelated to extrathyroidal extension and lymph node metastasis. PET positivity was related to larger tumour size and implied coexisting pathology. PET negativity or low SUV<sub>max</sub> suggested possible follicular variant PTC.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Papillary thyroid cancer</kwd>
<kwd>positron emission tomography–computed tomography (PET–CT)</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0300060513475743" sec-type="intro"><title>Introduction</title>
<p>Positron emission tomography (PET) using 2-deoxy-2-(<sup>18</sup>F)fluoro-<sc>d</sc>-glucose (<sup>18</sup>F-FDG) provides important tumour-related qualitative and quantitative metabolic information that is often critical for the diagnosis and follow-up of several cancers.<sup><xref ref-type="bibr" rid="bibr1-0300060513475743">1</xref></sup> Preoperative PET–CT has been shown to be clinically useful in gastric cancer, breast cancer and melanoma.<sup><xref ref-type="bibr" rid="bibr2-0300060513475743">2</xref>–<xref ref-type="bibr" rid="bibr4-0300060513475743">4</xref></sup></p>
<p>Preoperative PET–CT is not universally performed in patients with thyroid cancer because <sup>18</sup>F-FDG uptake depends on the degree of tumour cell differentiation, such that uptake is higher in poorly differentiated than in well-differentiated thyroid tumours.<sup><xref ref-type="bibr" rid="bibr5-0300060513475743">5</xref></sup> In addition, well-differentiated thyroid tumours with iodine avidity have low glucose metabolism, limiting the diagnostic value of PET–CT in thyroid cancer.<sup><xref ref-type="bibr" rid="bibr6-0300060513475743">6</xref></sup> PET is more useful in follow-up, for detecting recurrent or metastatic differentiated thyroid cancer in patients with negative radioiodine scans and elevated thyroglobulin levels.<sup><xref ref-type="bibr" rid="bibr7-0300060513475743">7</xref></sup></p>
<p>The aim of the present study was to evaluate preoperative PET–CT <sup>18</sup>F-FDG uptake in a group of patients with primary papillary thyroid cancer (PTC) with a wide range of clinicopathological features, in order to determine the usefulness of preoperative PET–CT in PTC.</p>
</sec>
<sec id="sec2-0300060513475743" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0300060513475743"><title>Study Population</title>
<p>This study involved consecutively recruited patients who underwent preoperative PET–CT and surgery for PTC at the Department of Surgery, Chung-Ang University Hospital, Seoul, Republic of Korea, between March 2011 and February 2012. PTC was preoperatively confirmed by fine-needle aspiration biopsy (FNAB) and diagnosed according to the National Cancer Institute classification system.<sup><xref ref-type="bibr" rid="bibr8-0300060513475743">8</xref></sup> Preoperative PET–CT was recommended for each patient. Patients who showed ambiguous <sup>18</sup>F-FDG uptake for primary lesions and diffuse high uptake for the surrounding thyroid tissue were excluded from the study because diffuse uptake by thyroiditis may mask uptake by primary thyroid cancer. Clinical and demographic data for the study cohort were determined by retrospective review of medical records. All patients underwent prophylactic central neck dissection. Additional selective lateral neck dissection was performed in those patients with clinically confirmed lateral neck lymph node metastases.</p>
<p>The study protocol was reviewed and approved by the Institutional Review Board of the Chung-Ang University Medical Centre, Seoul, Republic of Korea, and the requirement for informed consent was waived.</p>
</sec>
<sec id="sec4-0300060513475743"><title>PET–CT Scanning</title>
<p>A PET–CT scanner (Gemini TF, Philips, Hamburg, Germany) was used to perform <sup>18</sup>F-FDG PET–CT ≥7 days after FNAB. After fasting for ≥8 h, each patient received 370 MBq <sup>18</sup>F-FDG intravenous injection; PET–CT scanning was performed 60 min later. Patients were scanned from the middle of the skull to the upper thigh. PET images were reconstructed onto a 128 × 128 matrix using the ordered-subsets expectation maximization algorithm (four interactions and eight subsets) with attenuation correction. CT images were reconstructed onto a 512 × 512 matrix and converted using 511 keV equivalent attenuation factors for attenuation correction. PET, PET–CT and CT images were reviewed using a dedicated workstation. Extended Brilliance Workspace software (version 3.5.2.2260; Philips Medical Systems, Best, Netherlands) was used to construct three-dimensional displays (transaxial, coronal and sagittal) using CT, PET and PET–CT images, and the maximum intensity projection displays of PET data.</p>
<p>A single nuclear medicine specialist quantified <sup>18</sup>F-FDG uptake using standardized uptake values (SUV) calculated as follows: SUV = (decay corrected activity [kBq]/tissue volume [ml])/(injected <sup>18</sup>F-FDG activity [kBq]/body mass [g]). The SUV of a lesion was obtained by placing regions of interest (ROIs) manually around the lesion. The maximum SUV (SUV<sub>max</sub>) within a ROI was used to minimize partial volume effects. Any visually discernible <sup>18</sup>F-FDG uptake within thyroid nodules was classified as PET positive. If there was no visibly higher <sup>18</sup>F-FDG uptake than in the surrounding thyroid tissue, the tumour was classified as PET negative. For PET-negative results, the SUV<sub>max</sub> of PTC lesions were obtained by reference to ultrasonographic and CT images. The SUV<sub>max</sub> of PET-negative results was identical to the <sup>18</sup>F-FDG value of surrounding thyroid tissue.</p>
</sec>
<sec id="sec5-0300060513475743"><title>Histological Classification</title>
<p>An experienced pathologist (H.S.R.) reviewed tumour pathology after thyroidectomy and tumours were classified according World Health Organization guidelines for classification of PTC.<sup><xref ref-type="bibr" rid="bibr9-0300060513475743">9</xref></sup> Hashimoto’s thyroiditis was described according to histology, regardless of clinical symptoms or radiological findings.<sup><xref ref-type="bibr" rid="bibr10-0300060513475743">10</xref></sup> Multicentricity was defined as more than two tumour foci in ipsilateral or contralateral lobes. Extrathyroidal extension was diagnosed when carcinoma extended into perithyroidal soft tissue, including adipose tissue and skeletal muscle, as well as around sizeable vascular structures and nerves. Lymph node metastasis included central and lateral neck metastasis.</p>
</sec>
<sec id="sec6-0300060513475743"><title>Clinical and Demographic Definitions</title>
<p>Age was classified as younger (aged &lt;45 years) or older (aged ≥45 years), as suggested by the American Joint Committee on Cancer staging manual.<sup><xref ref-type="bibr" rid="bibr11-0300060513475743">11</xref></sup> Tumour size was classified as smaller (≤1 cm) or larger (&gt;1 cm).</p>
</sec>
<sec id="sec7-0300060513475743"><title>Statistical Analyses</title>
<p>Data were presented as <italic>n</italic> (%) of patients or median (interquartile range). Demographic and clinical data were compared using Pearson’s χ<sup>2</sup>-test or Fisher’s exact test. Clinicopathological parameters related to PET positivity were determined, and SUV<sub>max</sub> cut-off values were analysed by quantity analysis. The Kolmogorov–Smirnov goodness-of-fit test was performed to identify SUV<sub>max</sub> distribution and the Mann–Whitney <italic>U</italic>-test or Kruskal–Wallis tests were performed to analyse non-normally distributed data. Multivariate logistic regression analyses were performed to determine the factors associated with various clinicopathological parameters. A receiver operating characteristic curve was used to determine cut-off values for SUV<sub>max</sub>. Data were analysed using SPSS® software, version 12.0 (SPSS Inc., Chicago, IL, USA) for Windows®. A two-tailed <italic>P</italic>-value of &lt;0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="sec8-0300060513475743" sec-type="results"><title>Results</title>
<p>The study included 194 patients with FNAB-confirmed PTC (40 males/154 females; mean age 48.6 ± 13.4 years, age range 19–90 years). PET–CT revealed <sup>18</sup>F-FDG uptake for primary thyroid cancer in 138/194 of these patients (diagnostic sensitivity 71.7%). Postoperative histological findings revealed central lymph node metastasis in 70/194 patients (36.1%) and lateral neck lymph node metastasis in 24/194 (12.4%) patients. Preoperative PET–CT findings suggested central lymph node metastasis in three of 70 patients (sensitivity 4.3%). Preoperative PET–CT suggested the presence of lateral lymph node metastasis in 17 patients, two of whom were found to have no such metastasis, during surgery. The sensitivity of PET–CT for lateral neck lymph node metastasis was therefore 62.5% (15/24 patients), with a false-positive rate of 1.1% (two of 179 patients).</p>
<p>Demographic and clinicopathological characteristics of patients stratified according to PET positivity are shown in <xref ref-type="table" rid="table1-0300060513475743">Table 1</xref>. PET positivity was significantly associated with female sex (<italic>P</italic> = 0.004), larger tumour size (<italic>P</italic> &lt; 0.001) and presence of coexisting pathology (such as nodular hyperplasia or Hashimoto’s thyroiditis) (<italic>P</italic> = 0.001). The rate of PET positivity was significantly lower for follicular PTC variants than for other histological types (<italic>P</italic> = 0.001). Multivariate analysis determined that female sex, larger tumour size, presence of coexisting pathology and nonfollicular tumour type were significantly associated with positive PET findings (<xref ref-type="table" rid="table2-0300060513475743">Table 2</xref>).
<table-wrap id="table1-0300060513475743" position="float"><label>Table 1.</label><caption><p>Demographic, clinical and pathological characteristics of patients with fine-needle aspiration biopsy-confirmed primary papillary thyroid cancer (PTC), included in a study to evaluate the clinical usefulness of preoperative positron emission tomography–computed tomography (PET–CT), stratified according to PET-positivity<sup><xref ref-type="table-fn" rid="table-fn2-0300060513475743">a</xref></sup> (<italic>n</italic> = 194.</p></caption>
<graphic alternate-form-of="table1-0300060513475743" xlink:href="10.1177_0300060513475743-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristic</th>
<th>PET<sup>– </sup><italic>n</italic> = 56</th>
<th>PET<sup>+</sup><italic>n</italic> = 138</th>
<th>Statistical significance<sup><xref ref-type="table-fn" rid="table-fn3-0300060513475743">b</xref></sup></th>
</tr></thead>
<tbody align="left">
<tr>
<td>Sex</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Male</td>
<td>19 (33.9)</td>
<td>21 (15.2)</td>
<td><italic>P = </italic>0.004</td>
</tr>
<tr>
<td> Female</td>
<td>37 (66.1)</td>
<td>117 (84.8)</td>
<td/>
</tr>
<tr>
<td>Age, years</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> &lt;45</td>
<td>22 (39.3)</td>
<td>61 (44.2)</td>
<td>NS</td>
</tr>
<tr>
<td> ≥45</td>
<td>34 (60.7)</td>
<td>77 (55.8)</td>
<td/>
</tr>
<tr>
<td>Tumour size, cm</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> ≤1</td>
<td>49 (87.5)</td>
<td>77 (55.8)</td>
<td><italic>P</italic> &lt; 0.001</td>
</tr>
<tr>
<td> &gt;1</td>
<td>7 (12.5)</td>
<td>61 (44.2)</td>
<td/>
</tr>
<tr>
<td>Multicentricity</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Absence</td>
<td>31 (55.4)</td>
<td>71 (51.4)</td>
<td>NS</td>
</tr>
<tr>
<td> Presence</td>
<td>25 (44.6)</td>
<td>67 (48.6)</td>
<td/>
</tr>
<tr>
<td>Extrathyroidal extension</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Absence</td>
<td>43 (76.8)</td>
<td>87 (63.0)</td>
<td>NS</td>
</tr>
<tr>
<td> Presence</td>
<td>13 (23.2)</td>
<td>51 (37.0)</td>
<td/>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Absence</td>
<td>33 (58.9)</td>
<td>67 (48.6)</td>
<td>NS</td>
</tr>
<tr>
<td> Presence</td>
<td>23 (41.1)</td>
<td>71 (51.4)</td>
<td/>
</tr>
<tr>
<td>Coexisting pathology</td>
<td/>
<td/>
<td><italic>P = </italic>0.001</td>
</tr>
<tr>
<td> None</td>
<td>31 (55.4)</td>
<td>41 (29.7)</td>
<td/>
</tr>
<tr>
<td> NH</td>
<td>18 (32.1)</td>
<td>40 (29.0)</td>
<td/>
</tr>
<tr>
<td> HT</td>
<td>5 (8.9)</td>
<td>36 (26.1)</td>
<td/>
</tr>
<tr>
<td> NH + HT</td>
<td>2 (3.6)</td>
<td>21 (15.2)</td>
<td/>
</tr>
<tr>
<td>PTC subtype</td>
<td/>
<td/>
<td><italic>P = </italic>0.001</td>
</tr>
<tr>
<td> Classic</td>
<td>38 (67.9)</td>
<td>110 (79.7)</td>
<td/>
</tr>
<tr>
<td> Follicular</td>
<td>17 (30.4)</td>
<td>12 (8.7)</td>
<td/>
</tr>
<tr>
<td> Oncocytic</td>
<td>1 (1.8)</td>
<td>14 (10.1)</td>
<td/>
</tr>
<tr>
<td> Solid</td>
<td>0 (0.0)</td>
<td>1 (0.7)</td>
<td/>
</tr>
<tr>
<td> Tall cell</td>
<td>0 (0.0)</td>
<td>1 (0.7)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0300060513475743"><p>Data presented as <italic>n</italic> (%) of patients.</p></fn>
<fn id="table-fn2-0300060513475743"><label>a</label><p>Any visually discernible 2-deoxy-2-(<sup>18</sup>F)fluoro-<sc>d</sc>-glucose (<sup>18</sup>F-FDG) uptake within thyroid nodules was classified as PET positive.</p></fn>
<fn id="table-fn3-0300060513475743"><label>b</label><p>Pearson’s χ<sup>2</sup>-test.</p></fn>
<fn id="table-fn4-0300060513475743"><p>NS, not statistically significant (<italic>P</italic> ≥ 0.05); H, nodular hyperplasia; HT, Hashimoto’s thyroiditis.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0300060513475743" position="float"><label>Table 2.</label><caption><p>Logistic regression analysis of demographic, clinical and pathological characteristics associated with preoperative positron emission tomography (PET) positivity<sup><xref ref-type="table-fn" rid="table-fn5-0300060513475743">a</xref></sup> in patients with fine-needle aspiration biopsy-confirmed primary papillary thyroid cancer (PTC) (<italic>n</italic> = 194.</p></caption>
<graphic alternate-form-of="table2-0300060513475743" xlink:href="10.1177_0300060513475743-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristic</th>
<th>Hazard ratio</th>
<th>95% confidence intervals</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Sex</td>
<td/>
<td/>
</tr>
<tr>
<td> Male</td>
<td>1 (reference)</td>
<td/>
</tr>
<tr>
<td> Female</td>
<td>2.843</td>
<td>1.171, 6.905</td>
</tr>
<tr>
<td>Tumour size, cm</td>
<td/>
<td/>
</tr>
<tr>
<td> ≤1</td>
<td>1 (reference)</td>
<td/>
</tr>
<tr>
<td> &gt;1</td>
<td>8.090</td>
<td>3.000, 21.813</td>
</tr>
<tr>
<td>Coexisting pathology</td>
<td/>
<td/>
</tr>
<tr>
<td> Absence</td>
<td>1 (reference)</td>
<td/>
</tr>
<tr>
<td> Presence</td>
<td>2.983</td>
<td>1.393, 6.386</td>
</tr>
<tr>
<td>PTC subtype</td>
<td/>
<td/>
</tr>
<tr>
<td> Follicular</td>
<td>1 (reference)</td>
<td/>
</tr>
<tr>
<td> Nonfollicular</td>
<td>4.032</td>
<td>1.619, 10.038</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0300060513475743"><label>a</label><p>Any visually discernible 2-deoxy-2-(<sup>18</sup>F)fluoro-<sc>d</sc>-glucose (<sup>18</sup>F-FDG) uptake within thyroid nodules was classified as PET positive.</p></fn></table-wrap-foot>
</table-wrap></p>
<p><xref ref-type="table" rid="table3-0300060513475743">Table 3</xref> shows median SUV<sub>max</sub> values, stratified according to demographic and clinicopathological characteristics. SUV<sub>max</sub> values were significantly higher in females than males (<italic>P</italic> = 0.042), in larger tumours than smaller tumours (<italic>P</italic> = 0.001) and in the presence of extrathyroidal extension (<italic>P</italic> &lt; 0.001) or lymph node metastasis (<italic>P</italic> = 0.017), compared with the absence of these parameters. SUV<sub>max</sub> was significantly lower in follicular variants than in all other subtypes (<italic>P</italic> = 0.001).
<table-wrap id="table3-0300060513475743" position="float"><label>Table 3.</label><caption><p>Maximum standardized uptake value (SUV<sub>max</sub>) of preoperative positron emission tomography (PET) in patients with fine-needle aspiration biopsy-confirmed primary papillary thyroid cancer (PTC), stratified according to demographic, clinical and pathological characteristics (<italic>n</italic> = 194.</p></caption>
<graphic alternate-form-of="table3-0300060513475743" xlink:href="10.1177_0300060513475743-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristic</th>
<th><italic>n</italic></th>
<th>SUV<sub>max</sub></th>
<th>Statistical significance<sup><xref ref-type="table-fn" rid="table-fn7-0300060513475743">a</xref></sup></th>
</tr></thead>
<tbody align="left">
<tr>
<td>Sex</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Male</td>
<td>40</td>
<td>1.85 (0.00–4.18)</td>
<td><italic>P</italic> = 0.042</td>
</tr>
<tr>
<td> Female</td>
<td>154</td>
<td>2.70 (1.58–4.40)</td>
<td/>
</tr>
<tr>
<td>Age, years</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> &lt;45</td>
<td>83</td>
<td>2.70 (0.00–4.20)</td>
<td>NS</td>
</tr>
<tr>
<td> ≥45</td>
<td>111</td>
<td>2.50 (0.00–4.40)</td>
<td/>
</tr>
<tr>
<td>Tumour size, cm</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> ≤1</td>
<td>126</td>
<td>2.10 (0.00–3.00)</td>
<td><italic>P</italic> = 0.001</td>
</tr>
<tr>
<td> &gt;1</td>
<td>68</td>
<td>4.90 (2.90 –10.20)</td>
<td/>
</tr>
<tr>
<td>Multicentricity</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Absence</td>
<td>102</td>
<td>2.60 (0.00–4.53)</td>
<td>NS</td>
</tr>
<tr>
<td> Presence</td>
<td>92</td>
<td>2.60 (0.00–4.30)</td>
<td/>
</tr>
<tr>
<td>Extrathyroidal extension</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Absence</td>
<td>130</td>
<td>2.30 (0.00–3.30)</td>
<td><italic>P</italic> &lt; 0.001</td>
</tr>
<tr>
<td> Presence</td>
<td>64</td>
<td>4.00 (1.90–9.40)</td>
<td/>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Absence</td>
<td>100</td>
<td>2.40 (0.00–3.40)</td>
<td><italic>P</italic> = 0.017</td>
</tr>
<tr>
<td> Presence</td>
<td>94</td>
<td>3.00 (1.13–5.00)</td>
<td/>
</tr>
<tr>
<td>Coexisting pathology</td>
<td/>
<td/>
<td>NS<sup>b</sup></td>
</tr>
<tr>
<td> None</td>
<td>72</td>
<td>2.15 (1.88–4.23)</td>
<td/>
</tr>
<tr>
<td> NH</td>
<td>58</td>
<td>2.30 (0.00–4.15)</td>
<td/>
</tr>
<tr>
<td> HT</td>
<td>41</td>
<td>2.80 (2.40–4.10)</td>
<td/>
</tr>
<tr>
<td> NH + HT</td>
<td>23</td>
<td>3.45 (2.48–4.48)</td>
<td/>
</tr>
<tr>
<td>PTC subtype</td>
<td/>
<td/>
<td><italic>P</italic> = 0.001<sup>b</sup></td>
</tr>
<tr>
<td> Classic</td>
<td>148</td>
<td>2.75 (0.00–4.88)</td>
<td/>
</tr>
<tr>
<td> Follicular</td>
<td>29</td>
<td>1.18 (0.00–2.45)</td>
<td/>
</tr>
<tr>
<td> Oncocytic</td>
<td>15</td>
<td>2.90 (2.30–3.20)</td>
<td/>
</tr>
<tr>
<td> Solid</td>
<td>1</td>
<td>2.10 (NA)</td>
<td/>
</tr>
<tr>
<td> Tall cell</td>
<td>1</td>
<td>8.30 (NA)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0300060513475743"><p>Data presented as median (interquartile range).</p></fn>
<fn id="table-fn7-0300060513475743"><label>a</label><p>Mann–Whitney <italic>U</italic>-test; <sup>b</sup>Kruskal–Wallis test.</p></fn>
<fn id="table-fn8-0300060513475743"><p>NS, not statistically significant (<italic>P</italic> ≥ 0.05); NH, nodular hyperplasia; HT, Hashimoto’s thyroiditis; NA, range not available due to inclusion of only a single case.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>A cut-off SUV<sub>max</sub> of 2.9 resulted in sensitivity of 64.1% and specificity of 63.8% for diagnosis of extrathyroidal extension (<italic>P</italic> &lt; 0.001). Extrathyroidal extension was significantly associated with larger tumour size (<italic>P</italic> &lt; 0.001), lymph node metastasis (<italic>P</italic> = 0.001), nonfollicular tumour type (<italic>P</italic> = 0.018) and SUV<sub>max </sub>≥2.9 (<italic>P</italic> &lt; 0.001) (<xref ref-type="table" rid="table4-0300060513475743">Table 4</xref>). Multivariate analysis revealed that extrathyroidal extension was related to larger tumour size (relative risk [RR] 2.862; 95% confidence interval [CI] 1.375, 5.960) and lymph node metastasis (RR 2.359; 95% CI 1.120, 4.264), but not SUV<sub>max</sub> (RR 1.720; 95% CI 0.822, 3.600).
<table-wrap id="table4-0300060513475743" position="float"><label>Table 4.</label><caption><p>Demographic, clinical and pathological characteristics of patients with fine-needle aspiration biopsy-confirmed primary papillary thyroid cancer (PTC), stratified according to absence or presence of extrathyroidal extension (<italic>n</italic> = 194.</p></caption>
<graphic alternate-form-of="table4-0300060513475743" xlink:href="10.1177_0300060513475743-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristic</th>
<th>No extrathyroidal extension <italic>n</italic> = 130</th>
<th>Extrathyroidal extension <italic>n</italic> = 64</th>
<th>Statistical significance</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Sex</td>
<td/>
<td/>
<td>NS</td>
</tr>
<tr>
<td> Male</td>
<td>23 (17.7)</td>
<td>17 (26.6)</td>
<td/>
</tr>
<tr>
<td> Female</td>
<td>107 (82.3)</td>
<td>47 (73.4)</td>
<td/>
</tr>
<tr>
<td>Age, years</td>
<td/>
<td/>
<td>NS</td>
</tr>
<tr>
<td> &lt;45</td>
<td>56 (43.1)</td>
<td>27 (42.2)</td>
<td/>
</tr>
<tr>
<td> ≥45</td>
<td>74 (56.9)</td>
<td>37 (57.8)</td>
<td/>
</tr>
<tr>
<td>Tumour size, cm</td>
<td/>
<td/>
<td><italic>P</italic> &lt; 0.001<sup><xref ref-type="table-fn" rid="table-fn10-0300060513475743">a</xref></sup></td>
</tr>
<tr>
<td> ≤1</td>
<td>99 (76.2)</td>
<td>27 (42.2)</td>
<td/>
</tr>
<tr>
<td> &gt;1</td>
<td>31 (23.8)</td>
<td>37 (57.8)</td>
<td/>
</tr>
<tr>
<td>Multicentricity</td>
<td/>
<td/>
<td>NS</td>
</tr>
<tr>
<td> Absence</td>
<td>71 (54.6)</td>
<td>31 (48.4)</td>
<td/>
</tr>
<tr>
<td> Presence</td>
<td>59 (45.4)</td>
<td>33 (51.6)</td>
<td/>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td/>
<td/>
<td><italic>P</italic> = 0.001<sup><xref ref-type="table-fn" rid="table-fn10-0300060513475743">a</xref></sup></td>
</tr>
<tr>
<td> Absence</td>
<td>78 (60.0)</td>
<td>22 (34.4)</td>
<td/>
</tr>
<tr>
<td> Presence</td>
<td>52 (40.0)</td>
<td>42 (65.6)</td>
<td/>
</tr>
<tr>
<td>Coexisting pathology</td>
<td/>
<td/>
<td>NS</td>
</tr>
<tr>
<td> None</td>
<td>48 (36.9)</td>
<td>24 (37.5)</td>
<td/>
</tr>
<tr>
<td> NH</td>
<td>37 (28.5)</td>
<td>21 (32.8)</td>
<td/>
</tr>
<tr>
<td> HT</td>
<td>30 (23.1)</td>
<td>11 (17.2)</td>
<td/>
</tr>
<tr>
<td> NH + HT</td>
<td>15 (11.5)</td>
<td>8 (12.5)</td>
<td/>
</tr>
<tr>
<td>PTC subtype</td>
<td/>
<td/>
<td><italic>P</italic> = 0.018<sup>b</sup></td>
</tr>
<tr>
<td> Follicular</td>
<td>25 (19.2)</td>
<td>4 (6.3)</td>
<td/>
</tr>
<tr>
<td> Nonfollicular</td>
<td>105 (80.8)</td>
<td>60 (93.8)</td>
<td/>
</tr>
<tr>
<td>SUV<sub>max</sub></td>
<td/>
<td/>
<td><italic>P</italic> &lt; 0.001<sup><xref ref-type="table-fn" rid="table-fn10-0300060513475743">a</xref></sup></td>
</tr>
<tr>
<td> &lt;2.9</td>
<td>84 (64.6)</td>
<td>23 (35.9)</td>
<td/>
</tr>
<tr>
<td> ≥2.9</td>
<td>46 (35.4)</td>
<td>41 (64.1)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0300060513475743"><p>Data presented as <italic>n</italic> (%) of patients.</p></fn>
<fn id="table-fn10-0300060513475743"><label>a</label><p>Pearson’s χ<sup>2</sup>-test; <sup>b</sup>Fisher’s exact test.</p></fn>
<fn id="table-fn11-0300060513475743"><p>NS, not statistically significant (<italic>P</italic> ≥ 0.05); NH, nodular hyperplasia; HT, Hashimoto’s thyroiditis; SUV<sub>max</sub>, maximum standardized uptake value.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>A cut-off SUV<sub>max</sub> of 2.9 resulted in sensitivity of 52.1% and specificity of 69.0% for lymph node metastasis (<italic>P</italic> &lt; 0.001). Lymph node metastasis was significantly associated with younger age (<italic>P</italic> &lt; 0.001), larger tumour size (<italic>P</italic> = 0.002), extrathyroidal extension (<italic>P</italic> = 0.001), nonfollicular tumour type (<italic>P</italic> = 0.042) and SUV<sub>max </sub>≥2.9 (<italic>P</italic> = 0.048) (<xref ref-type="table" rid="table5-0300060513475743">Table 5</xref>). Multivariate analysis found that lymph node metastasis was related to younger age (RR 4.026; 95% CI 2.125, 7.628) and extrathyroidal extension (RR 2.725; 95% CI 1.242, 5.130), but not to SUV<sub>max</sub> (RR 0.970; 95% CI 0.467, 2.016).
<table-wrap id="table5-0300060513475743" position="float"><label>Table 5.</label><caption><p>Demographic, clinical and pathological characteristics of patients with fine-needle aspiration biopsy-confirmed primary papillary thyroid cancer (PTC), stratified according to absence or presence of lymph node metastasis (<italic>n</italic> = 194.</p></caption>
<graphic alternate-form-of="table5-0300060513475743" xlink:href="10.1177_0300060513475743-table5.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristic</th>
<th>No metastasis <italic>n</italic> = 100</th>
<th>Metastasis <italic>n</italic> = 94</th>
<th>Statistical significance<sup><xref ref-type="table-fn" rid="table-fn13-0300060513475743">a</xref></sup></th>
</tr></thead>
<tbody align="left">
<tr>
<td>Sex</td>
<td/>
<td/>
<td>NS</td>
</tr>
<tr>
<td> Male</td>
<td>19 (19.0)</td>
<td>21 (22.3)</td>
<td/>
</tr>
<tr>
<td> Female</td>
<td>81 (81.0)</td>
<td>73 (77.7)</td>
<td/>
</tr>
<tr>
<td>Age, years</td>
<td/>
<td/>
<td><italic>P</italic> &lt; 0.001</td>
</tr>
<tr>
<td> &lt;45</td>
<td>28 (28.0)</td>
<td>55 (58.5)</td>
<td/>
</tr>
<tr>
<td> ≥45</td>
<td>72 (72.0)</td>
<td>39 (41.5)</td>
<td/>
</tr>
<tr>
<td>Tumour size, cm</td>
<td/>
<td/>
<td><italic>P = </italic>0.002</td>
</tr>
<tr>
<td> ≤1</td>
<td>75 (75.0)</td>
<td>51 (54.3)</td>
<td/>
</tr>
<tr>
<td> &gt;1</td>
<td>25 (25.0)</td>
<td>43 (45.7)</td>
<td/>
</tr>
<tr>
<td>Multicentricity</td>
<td/>
<td/>
<td>NS</td>
</tr>
<tr>
<td> Absence</td>
<td>55 (55.0)</td>
<td>47 (50.0)</td>
<td/>
</tr>
<tr>
<td> Presence</td>
<td>45 (45.0)</td>
<td>47 (50.0)</td>
<td/>
</tr>
<tr>
<td>Extrathyroidal extension</td>
<td/>
<td/>
<td><italic>P</italic> = 0.001</td>
</tr>
<tr>
<td> Absence</td>
<td>78 (78.0)</td>
<td>52 (55.3)</td>
<td/>
</tr>
<tr>
<td> Presence</td>
<td>22 (22.0)</td>
<td>42 (44.7)</td>
<td/>
</tr>
<tr>
<td>Coexisting pathology</td>
<td/>
<td/>
<td>NS</td>
</tr>
<tr>
<td> None</td>
<td>35 (35.0)</td>
<td>37 (39.4)</td>
<td/>
</tr>
<tr>
<td> NH</td>
<td>35 (35.0)</td>
<td>23 (24.5)</td>
<td/>
</tr>
<tr>
<td> HT</td>
<td>16 (16.0)</td>
<td>25 (26.6)</td>
<td/>
</tr>
<tr>
<td> NH + HT</td>
<td>14 (14.0)</td>
<td>9 (9.6)</td>
<td/>
</tr>
<tr>
<td>PTC subtype</td>
<td/>
<td/>
<td><italic>P</italic> = 0.042</td>
</tr>
<tr>
<td> Follicular</td>
<td>20 (20.0)</td>
<td>9 (9.6)</td>
<td/>
</tr>
<tr>
<td> Nonfollicular</td>
<td>80 (80.0)</td>
<td>85 (90.4)</td>
<td/>
</tr>
<tr>
<td>SUV<sub>max</sub></td>
<td/>
<td/>
<td><italic>P = </italic>0.048</td>
</tr>
<tr>
<td> &lt;2.9</td>
<td>62 (62.0)</td>
<td>45 (47.9)</td>
<td/>
</tr>
<tr>
<td> ≥2.9</td>
<td>38 (38.0)</td>
<td>49 (52.1)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn12-0300060513475743"><p>Data presented as <italic>n</italic> (%) of patients.</p></fn>
<fn id="table-fn13-0300060513475743"><label>a</label><p>Pearson’s χ<sup>2</sup>-test.</p></fn>
<fn id="table-fn14-0300060513475743"><p>NS, not statistically significant (<italic>P</italic> ≥ 0.05); NH, nodular hyperplasia; HT, Hashimoto’s thyroiditis; SUV<sub>max</sub>, maximum standardized uptake value.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The SUV<sub>max</sub> cut-off for follicular PTC was defined as 2.0 (sensitivity 70.9%, specificity 69.0%, <italic>P</italic> &lt; 0.001). Follicular PTC was associated with absence of extrathyroidal extension (<italic>P</italic> = 0.018), absence of lymph node metastasis (<italic>P</italic> = 0.042), and SUV<sub>max</sub> &lt;2.0 (<italic>P</italic> &lt; 0.001) (<xref ref-type="table" rid="table6-0300060513475743">Table 6</xref>). Of these three parameters, only SUV<sub>max</sub> &lt;2.0 was significantly associated with follicular PTC in multivariate analysis (<xref ref-type="table" rid="table7-0300060513475743">Table 7</xref>).
<table-wrap id="table6-0300060513475743" position="float"><label>Table 6.</label><caption><p>Demographic, clinical and pathological characteristics of patients with fine-needle aspiration biopsy-confirmed primary papillary thyroid cancer (PTC), stratified according to histological subtype (nonfollicular or follicular; <italic>n</italic> = 194.</p></caption>
<graphic alternate-form-of="table6-0300060513475743" xlink:href="10.1177_0300060513475743-table6.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristic</th>
<th>Nonfollicular <italic>n</italic> = 165</th>
<th>Follicular <italic>n</italic> = 29</th>
<th>Statistical significance<sup><xref ref-type="table-fn" rid="table-fn16-0300060513475743">a</xref></sup></th>
</tr></thead>
<tbody align="left">
<tr>
<td>Sex</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Male</td>
<td>32 (19.4)</td>
<td>8 (27.6)</td>
<td>NS</td>
</tr>
<tr>
<td> Female</td>
<td>133 (80.6)</td>
<td>21 (72.4)</td>
<td/>
</tr>
<tr>
<td>Age, years</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> &lt;45</td>
<td>72 (43.6)</td>
<td>11(37.9)</td>
<td>NS</td>
</tr>
<tr>
<td> ≥45</td>
<td>93 (56.4)</td>
<td>18 (62.1)</td>
<td/>
</tr>
<tr>
<td>Tumour size, cm</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> ≤1</td>
<td>103 (62.4)</td>
<td>23 (79.3)</td>
<td>NS</td>
</tr>
<tr>
<td> &gt;1</td>
<td>62 (37.6)</td>
<td>6 (20.7)</td>
<td/>
</tr>
<tr>
<td>Multicentricity</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Absence</td>
<td>85 (51.5)</td>
<td>17 (58.6)</td>
<td>NS</td>
</tr>
<tr>
<td> Presence</td>
<td>80 (48.5)</td>
<td>12 (41.4)</td>
<td/>
</tr>
<tr>
<td>Extrathyroidal extension</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Absence</td>
<td>105 (63.6)</td>
<td>25 (86.2)</td>
<td><italic>P</italic> = 0.018</td>
</tr>
<tr>
<td> Presence</td>
<td>60 (36.4)</td>
<td>4 (13.8)</td>
<td/>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td> Absence</td>
<td>80 (48.5)</td>
<td>20 (69.0)</td>
<td><italic>P</italic> = 0.042</td>
</tr>
<tr>
<td> Presence</td>
<td>85 (51.5)</td>
<td>9 (31.0)</td>
<td/>
</tr>
<tr>
<td>Coexisting pathology</td>
<td/>
<td/>
<td>NS</td>
</tr>
<tr>
<td> None</td>
<td>59 (35.8)</td>
<td>13 (44.8)</td>
<td/>
</tr>
<tr>
<td> NH</td>
<td>48 (29.1)</td>
<td>10 (34.5)</td>
<td/>
</tr>
<tr>
<td> HT</td>
<td>36 (21.8)</td>
<td>5 (17.2)</td>
<td/>
</tr>
<tr>
<td> NH + HT</td>
<td>22 (13.3)</td>
<td>1 (3.4)</td>
<td/>
</tr>
<tr>
<td>SUV<sub>max</sub></td>
<td/>
<td/>
<td><italic>P</italic> &lt; 0.001</td>
</tr>
<tr>
<td> &lt;2.0</td>
<td>48 (29.1)</td>
<td>20 (69.0)</td>
<td/>
</tr>
<tr>
<td> ≥2.0</td>
<td>117 (70.9)</td>
<td>9 (31.0)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn15-0300060513475743"><p>Data presented as <italic>n</italic> (%) of patients.</p></fn>
<fn id="table-fn16-0300060513475743"><label>a</label><p>Pearson’s χ<sup>2</sup>-test.</p></fn>
<fn id="table-fn17-0300060513475743"><p>NS, not statistically significant (<italic>P</italic> ≥ 0.05); NH, nodular hyperplasia; HT, Hashimoto’s thyroiditis; SUV<sub>max</sub>, maximum standardized uptake value.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table7-0300060513475743" position="float"><label>Table 7.</label><caption><p>Logistic regression analysis of clinical and pathological characteristics associated with follicular histological subtypes of primary papillary thyroid cancer (<italic>n</italic> = 194.</p></caption>
<graphic alternate-form-of="table7-0300060513475743" xlink:href="10.1177_0300060513475743-table7.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristic</th>
<th>Hazard ratio</th>
<th>95% confidence intervals</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Extrathyroidal extension</td>
<td/>
<td/>
</tr>
<tr>
<td> Absence</td>
<td>2.690</td>
<td>0.851, 8.502</td>
</tr>
<tr>
<td> Presence</td>
<td>1 (reference)</td>
<td/>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td/>
<td/>
</tr>
<tr>
<td> Absence</td>
<td>1.964</td>
<td>0.800, 4.820</td>
</tr>
<tr>
<td> Presence</td>
<td>1 (reference)</td>
<td/>
</tr>
<tr>
<td>SUV<sub>max</sub> of primary lesion</td>
<td/>
<td/>
</tr>
<tr>
<td> &lt;2.0</td>
<td>5.044</td>
<td>2.111, 12.056</td>
</tr>
<tr>
<td> ≥2.0</td>
<td>1 (reference)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn18-0300060513475743"><p>SUV<sub>max</sub>, maximum standardized uptake value.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec9-0300060513475743" sec-type="discussion"><title>Discussion</title>
<p>The sensitivity of preoperative <sup>18</sup>F-FDG PET–CT for thyroid cancer has been reported to be 60% in unclassified tumour types.<sup><xref ref-type="bibr" rid="bibr12-0300060513475743">12</xref></sup> The present study found a PET-positive rate of 71.7%, and significant associations between positivity and clinicopathological parameters including female sex, larger tumour size, nonfollicular tumour type and presence of coexisting pathology (nodular hyperplasia or Hashimoto’s thyroiditis).</p>
<p>The presence of a positive PET signal indicates increased glucose and <sup>18</sup>F-FDG uptake in a cancer cell. Tumours in female patients were more frequently PET positive and had higher quantitative <sup>18</sup>F-FDG values than those in male patients, in the present study. Studies have indicated a poorer prognosis of well-differentiated thyroid cancer in men than in women.<sup><xref ref-type="bibr" rid="bibr13-0300060513475743">13</xref>,<xref ref-type="bibr" rid="bibr14-0300060513475743">14</xref></sup> In addition, it has been suggested that <sup>18</sup>F-FDG uptake in differentiated thyroid cancer is a sign of higher-grade malignancy,<sup><xref ref-type="bibr" rid="bibr15-0300060513475743">15</xref></sup> and there may be a relationship between solute carrier family 2 (facilitated glucose transporter), member 1 (<italic>SLC2A1</italic>) expression and thyroid neoplasms with unfavourable prognosis.<sup><xref ref-type="bibr" rid="bibr16-0300060513475743">16</xref></sup> Taken together, these data suggest that <sup>18</sup>F-FDG uptake would be higher in male patients than in females, but the findings of the present study indicate otherwise. Some reports have suggested that the patient’s sex is unrelated to prognosis.<sup><xref ref-type="bibr" rid="bibr11-0300060513475743">11</xref>,<xref ref-type="bibr" rid="bibr17-0300060513475743">17</xref></sup> In any case, it is clear that further studies are required to elucidate the relationship between <sup>18</sup>F-FDG uptake and sex.</p>
<p>The presence of coexisting pathologies (such as nodular hyperplasia or Hashimoto’s thyroiditis) significantly increased the likelihood of PET positivity in the present study. No previous report has shown a relationship between PET positivity and coexisting benign thyroid disease. The phosphatidylinositol 3-kinase(PI3K)/protein kinase B (Akt) pathway has been found to be involved in both Hashimoto’s thyroiditis and well-differentiated thyroid cancer.<sup><xref ref-type="bibr" rid="bibr18-0300060513475743">18</xref></sup> It is possible, therefore, that other molecules (such as those related to <sup>18</sup>F-FDG uptake) may be coexpressed in thyroid cancer with thyroiditis. Evidence suggests that nodular hyperplasia itself may be PET positive,<sup><xref ref-type="bibr" rid="bibr19-0300060513475743">19</xref></sup> leading to possible confusion between the PET signals of these two conditions. The absence of any significant differences in median SUV<sub>max</sub> between PTC (with or without coexisting pathologies) in the present study may have been due to the relatively small study cohort.</p>
<p>Follicular variant PTC was significantly less likely to be PET positive and had significantly lower SUV<sub>max</sub> than other subtypes, in the present study. The clinical implications of follicular variant PTC have not yet been clearly elucidated. Some studies have reported that the follicular variant had preferable clinicopathological features to the classic type;<sup><xref ref-type="bibr" rid="bibr20-0300060513475743">20</xref>,<xref ref-type="bibr" rid="bibr21-0300060513475743">21</xref></sup> others showed no between-group differences.<sup><xref ref-type="bibr" rid="bibr22-0300060513475743">22</xref>,<xref ref-type="bibr" rid="bibr23-0300060513475743">23</xref></sup> It has been suggested that central node dissection may be unnecessary in follicular variant PTC because of the absence of central lymph node metastasis.<sup><xref ref-type="bibr" rid="bibr24-0300060513475743">24</xref></sup> Data from the present study suggest that PET negativity may be helpful for preoperative determination of follicular variant PTC.</p>
<p>It has been suggested that PET positivity in papillary thyroid microcarcinomas (i.e. those that are ≤1 cm) implies lymph node metastasis and extracapsular tumour extension.<sup><xref ref-type="bibr" rid="bibr25-0300060513475743">25</xref></sup> In contrast, others have shown that PET positivity is unrelated to extrathyroidal extension.<sup><xref ref-type="bibr" rid="bibr26-0300060513475743">26</xref></sup> Extrathyroidal extension was associated with larger tumour size in the present study, and tumour size was related in turn to PET positivity and high SUV<sub>max</sub>. When considering the relationships between independent variables such as tumour size, subtype, lymph node metastasis and SUV<sub>max</sub>, PET positivity was not an independent factor for extrathyroidal extension. Other studies did not consider the PTC subtype,<sup><xref ref-type="bibr" rid="bibr25-0300060513475743">25</xref>,<xref ref-type="bibr" rid="bibr26-0300060513475743">26</xref></sup> which may act as a confounding factor. The rate of extrathyroidal extension is thought to differ between study centres due to subjectivity in the criteria for defining minimum extrathyroidal extension.<sup><xref ref-type="bibr" rid="bibr27-0300060513475743">27</xref></sup> In a similar manner, the presence of lymph node metastasis could differ according to the bounds of central neck dissection. These differences could affect the relationships between <sup>18</sup>F-FDG uptake and extrathyroidal extension or lymph node metastasis. Prospective, multicentre studies with common pathological criteria defining extrathyroidal extension and PTC subtype, in addition to common principles for central neck dissection, would be needed to overcome this interobserver variability.</p>
<p>In conclusion, the value of preoperative PET–CT in PTC remains unclear. PET-positive results and high SUV<sub>max</sub> were not related to significant clinical factors such as extrathyroidal extension or lymph node metastasis, in the present study. PET positivity was, however, related to larger tumour size and indicated possible coexisting pathology. In addition, PET negativity or low SUV<sub>max</sub> suggested possible follicular variant PTC.</p>
</sec>
</body>
<back><ack>
<title>Acknowledgement</title>
<p>The authors thank Dr. JW Seok (Department of Nuclear Medicine, Chung-Ang University Hospital, Seoul, Republic of Korea) for his assistance in reviewing PET–CT images.</p>
</ack>
<sec id="sec14-0300060513475743">
<title>Declaration of Conflicting Interest</title>
<p>The authors declare that there are no conflicts of interest.</p>
</sec>
<sec id="sec15-0300060513475743">
<title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0300060513475743"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>V</given-names></name><name><surname>McCook</surname><given-names>BM</given-names></name><name><surname>Torok</surname><given-names>FS</given-names></name></person-group>. <article-title>An introduction to PET–CT imaging</article-title>. <source>Radiographics</source> <year>2004</year>; <volume>24</volume>: <fpage>523</fpage>–<lpage>543</lpage>.</citation></ref>
<ref id="bibr2-0300060513475743"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>HH</given-names></name><name><surname>Lee</surname><given-names>SE</given-names></name><name><surname>Choi</surname><given-names>IS</given-names></name><etal/></person-group>. <article-title>The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer</article-title>. <source>J Surg Oncol</source> <year>2011</year>; <volume>104</volume>: <fpage>530</fpage>–<lpage>533</lpage>.</citation></ref>
<ref id="bibr3-0300060513475743"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fuster</surname><given-names>D</given-names></name><name><surname>Duch</surname><given-names>J</given-names></name><name><surname>Paredes</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Preoperative staging of large primary breast cancer with [<sup>18</sup>F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures</article-title>. <source>J Clin Oncol</source> <year>2008</year>; <volume>26</volume>: <fpage>4746</fpage>–<lpage>4751</lpage>.</citation></ref>
<ref id="bibr4-0300060513475743"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brady</surname><given-names>MS</given-names></name><name><surname>Akhurst</surname><given-names>T</given-names></name><name><surname>Spanknebel</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Utility of preoperative [(18)]F Fluorodeoxyglucose–positron emission tomography scanning in high-risk melanoma patients</article-title>. <source>Ann Surg Oncol</source> <year>2006</year>; <volume>13</volume>: <fpage>525</fpage>–<lpage>532</lpage>.</citation></ref>
<ref id="bibr5-0300060513475743"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Are</surname><given-names>C</given-names></name><name><surname>Hsu</surname><given-names>JF</given-names></name><name><surname>Ghossein</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas</article-title>. <source>Ann Surg Oncol</source> <year>2007</year>; <volume>14</volume>: <fpage>3210</fpage>–<lpage>3215</lpage>.</citation></ref>
<ref id="bibr6-0300060513475743"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sundram</surname><given-names>F</given-names></name></person-group>. <article-title>Clinical use of PET/CT in thyroid cancer diagnosis and management</article-title>. <source>Biomed Imaging Interv J</source> <year>2006</year>; <volume>2</volume>: <fpage>e56</fpage>–<lpage>e56</lpage>.</citation></ref>
<ref id="bibr7-0300060513475743"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Oriuchi</surname><given-names>N</given-names></name><name><surname>Higuchi</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>PET in the follow-up of differentiated thyroid cancer</article-title>. <source>Br J Radiol</source> <year>2003</year>; <volume>76</volume>: <fpage>690</fpage>–<lpage>695</lpage>.</citation></ref>
<ref id="bibr8-0300060513475743"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baloch</surname><given-names>ZW</given-names></name><name><surname>Cibas</surname><given-names>ES</given-names></name><name><surname>Clark</surname><given-names>DP</given-names></name><etal/></person-group>. <article-title>The National Cancer Institute Thyroid fine needle aspiration state of the science conference: a summation</article-title>. <source>Cytojournal</source> <year>2008</year>; <volume>5</volume>: <fpage>6</fpage>–<lpage>6</lpage>.</citation></ref>
<ref id="bibr9-0300060513475743"><label>9</label><citation citation-type="book"><person-group person-group-type="editor"><name><surname>DeLellis</surname><given-names>RA</given-names></name><name><surname>Lloyd</surname><given-names>RV</given-names></name><name><surname>Heitz</surname><given-names>PU</given-names></name><etal/></person-group> (Eds) <source>World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs</source> <publisher-loc>Lyon</publisher-loc>: <publisher-name>IARC Press</publisher-name>, <year>2004</year>.</citation></ref>
<ref id="bibr10-0300060513475743"><label>10</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Maitra</surname><given-names>A</given-names></name></person-group>. <article-title>The endocrine system</article-title>. In: <person-group person-group-type="editor"><name><surname>Kumar</surname><given-names>V</given-names></name></person-group> (ed.) <source>Robbins and Cotran Pathologic basis of disease</source> <edition>8th edn</edition>, <publisher-loc>Philidelphia</publisher-loc>: <publisher-name>Elsevier</publisher-name>, <year>2009</year>, <fpage>1112</fpage>–<lpage>1113</lpage>.</citation></ref>
<ref id="bibr11-0300060513475743"><label>11</label><citation citation-type="book"><person-group person-group-type="editor"><name><surname>Edge</surname><given-names>SB</given-names></name><name><surname>Byrd</surname><given-names>DR</given-names></name><name><surname>Compton</surname><given-names>CC</given-names></name><etal/></person-group> (Eds) <source>AJCC Cancer Staging Manual</source> <edition>7th edn</edition>, <publisher-loc>New York</publisher-loc>: <publisher-name>Springer</publisher-name>, <year>2010</year>.</citation></ref>
<ref id="bibr12-0300060513475743"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kingpetch</surname><given-names>K</given-names></name><name><surname>Pipatrattana</surname><given-names>R</given-names></name><name><surname>Tepmongkol</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Utility of 18F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody</article-title>. <source>J Med Assoc Thai</source> <year>2011</year>; <volume>94</volume>: <fpage>1238</fpage>–<lpage>1244</lpage>.</citation></ref>
<ref id="bibr13-0300060513475743"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Byar</surname><given-names>DP</given-names></name><name><surname>Green</surname><given-names>SB</given-names></name><name><surname>Dor</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group</article-title>. <source>Eur J Cancer</source> <year>1979</year>; <volume>15</volume>: <fpage>1033</fpage>–<lpage>1041</lpage>.</citation></ref>
<ref id="bibr14-0300060513475743"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DeGroot</surname><given-names>LJ</given-names></name><name><surname>Kaplan</surname><given-names>EL</given-names></name><name><surname>McCormick</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Natural history, treatment, and course of papillary thyroid carcinoma</article-title>. <source>J Clin Endocrinol Metab</source> <year>1990</year>; <volume>71</volume>: <fpage>414</fpage>–<lpage>424</lpage>.</citation></ref>
<ref id="bibr15-0300060513475743"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feine</surname><given-names>U</given-names></name><name><surname>Lietzenmayer</surname><given-names>R</given-names></name><name><surname>Hanke</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I</article-title>. <source>Nuklearmedizin</source> <year>1995</year>; <volume>34</volume>: <fpage>127</fpage>–<lpage>134</lpage>. <comment>[in German, English abstract]</comment>.</citation></ref>
<ref id="bibr16-0300060513475743"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schönberger</surname><given-names>J</given-names></name><name><surname>Rüschoff</surname><given-names>J</given-names></name><name><surname>Grimm</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study</article-title>. <source>Thyroid</source> <year>2002</year>; <volume>12</volume>: <fpage>747</fpage>–<lpage>754</lpage>.</citation></ref>
<ref id="bibr17-0300060513475743"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cady</surname><given-names>B</given-names></name><name><surname>Rossi</surname><given-names>R</given-names></name></person-group>. <article-title>An expanded view of risk-group definition in differentiated thyroid carcinoma</article-title>. <source>Surgery</source> <year>1988</year>; <volume>104</volume>: <fpage>947</fpage>–<lpage>953</lpage>.</citation></ref>
<ref id="bibr18-0300060513475743"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Larson</surname><given-names>SD</given-names></name><name><surname>Jackson</surname><given-names>LN</given-names></name><name><surname>Riall</surname><given-names>TS</given-names></name><etal/></person-group>. <article-title>Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway</article-title>. <source>J Am Coll Surg</source> <year>2007</year>; <volume>204</volume>: <fpage>764</fpage>–<lpage>775</lpage>.</citation></ref>
<ref id="bibr19-0300060513475743"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>TY</given-names></name><name><surname>Liou</surname><given-names>MJ</given-names></name><name><surname>Lin</surname><given-names>KJ</given-names></name><etal/></person-group>. <article-title>Prevalence and significance of thyroid uptake detected by <sup>18</sup>F-FDG PET</article-title>. <source>Endocrine</source> <year>2011</year>; <volume>40</volume>: <fpage>297</fpage>–<lpage>302</lpage>.</citation></ref>
<ref id="bibr20-0300060513475743"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burningham</surname><given-names>AR</given-names></name><name><surname>Krishnan</surname><given-names>J</given-names></name><name><surname>Davidson</surname><given-names>BJ</given-names></name><etal/></person-group>. <article-title>Papillary and follicular variant of papillary carcinoma of the thyroid: initial presentation and response to therapy</article-title>. <source>Otolaryngol Head Neck Surg</source> <year>2005</year>; <volume>132</volume>: <fpage>840</fpage>–<lpage>844</lpage>.</citation></ref>
<ref id="bibr21-0300060513475743"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>BH</given-names></name><name><surname>Lo</surname><given-names>CY</given-names></name><name><surname>Chan</surname><given-names>WF</given-names></name><etal/></person-group>. <article-title>Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome</article-title>. <source>World J Surg</source> <year>2006</year>; <volume>30</volume>: <fpage>752</fpage>–<lpage>758</lpage>.</citation></ref>
<ref id="bibr22-0300060513475743"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HW</given-names></name><name><surname>Bhattacharyya</surname><given-names>N</given-names></name></person-group>. <article-title>Clinical behavior of follicular variant of papillary thyroid carcinoma: presentation and survival</article-title>. <source>Laryngoscope</source> <year>2010</year>; <volume>120</volume>: <fpage>712</fpage>–<lpage>716</lpage>.</citation></ref>
<ref id="bibr23-0300060513475743"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zidan</surname><given-names>J</given-names></name><name><surname>Karen</surname><given-names>D</given-names></name><name><surname>Stein</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival</article-title>. <source>Cancer</source> <year>2003</year>; <volume>97</volume>: <fpage>1181</fpage>–<lpage>1185</lpage>.</citation></ref>
<ref id="bibr24-0300060513475743"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salter</surname><given-names>KD</given-names></name><name><surname>Andersen</surname><given-names>PE</given-names></name><name><surname>Cohen</surname><given-names>JI</given-names></name><etal/></person-group>. <article-title>Central nodal metastases in papillary thyroid carcinoma based on tumor histologic type and focality</article-title>. <source>Arch Otolaryngol Head Neck Surg</source> <year>2010</year>; <volume>136</volume>: <fpage>692</fpage>–<lpage>696</lpage>.</citation></ref>
<ref id="bibr25-0300060513475743"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname><given-names>M</given-names></name><name><surname>Noh</surname><given-names>TW</given-names></name><name><surname>Cho</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Visually discernible [<sup>18</sup>F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor</article-title>. <source>J Clin Endocrinol Metab</source> <year>2010</year>; <volume>95</volume>: <fpage>3182</fpage>–<lpage>3188</lpage>.</citation></ref>
<ref id="bibr26-0300060513475743"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>HS</given-names></name><name><surname>Chung</surname><given-names>M</given-names></name><name><surname>Baek</surname><given-names>CH</given-names></name><etal/></person-group>. <article-title>Can [<sup>18</sup>F]-fluorodeoxyglucose standardized uptake values of PET imaging predict pathologic extrathyroid invasion of thyroid papillary microcarcinomas?</article-title> <source>Laryngoscope</source> <year>2006</year>; <volume>116</volume>: <fpage>2133</fpage>–<lpage>2137</lpage>.</citation></ref>
<ref id="bibr27-0300060513475743"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghossein</surname><given-names>R</given-names></name></person-group>. <article-title>Update to the College of American Pathologists reporting on thyroid carcinomas</article-title>. <source>Head Neck Pathol</source> <year>2009</year>; <volume>3</volume>: <fpage>86</fpage>–<lpage>93</lpage>.</citation></ref>
</ref-list>
</back>
</article>